AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal
Mitochondrial Biomarkers in Human Neurological Disorders
Mitochondrial dysfunction is identified as a common issue in neurological disorders, including multiple sclerosis. Studies show that mitochondrial biomarkers can enhance diagnostic accuracy and help in monitoring disease progression and treatment response.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
Understanding mitochondrial dysfunction's role can lead to better diagnostic tools and patient management strategies in multiple sclerosis and related disorders.
What this does not prove
Despite potential benefits, clinical use of these biomarkers is hindered by variability and lack of specificity.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- fluid biomarkers; genetic biomarkers; multi-omics approaches; imaging biomarkers
- Safety
- Not reported
Original sources
- Primary evidenceMitochondrial dysfunction in neurology: biomarkers and clinical implications. ↗DOI: 10.1038/s41582-026-01274-z
Supporting passages (7)
publication datePublication date: 2026-10-23
findingsMitochondrial dysfunction is increasingly recognized as a shared downstream pathogenic mechanism across a wide spectrum of neurological disorders, ranging from primary mitochondrial diseases to conditions including amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, multiple sclerosis, hereditary ataxias and idiopathic inflammatory myopathies.
findingsThis Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response.
limitationsHowever, clinical implementation remains limited by methodological heterogeneity, biological variability and reduced disease specificity.
biomarkersMitochondrial biomarkers can be broadly categorized into four domains: fluid biomarkers, reflecting metabolic alterations and stress signalling; genetic biomarkers, capturing mitochondrial DNA integrity and dynamics; multi-omics approaches, integrating transcriptomic, proteomic and metabolomic signatures; and imaging biomarkers, enabling in vivo assessment of structural and functional consequences of mitochondrial dysfunction.
peer reviewedPublication types: Journal Article; Review
subjectsThis Review examines the role of mitochondrial biomarkers in improving diagnostic accuracy, patient stratification and monitoring of disease progression and therapeutic response.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.